Hepatic Venous Pressure Gradient Versus Endoscopic Ultrasound-Guided Portal Pressure Gradient - Comparative Analysis (HEPCA)

Summary

The goal of this interventional trial is to compare in measuring of portal hypertension by HVPG and EUS-PPG in subject indicated to HVPG measurement.

The primary question is whether EUS-PPG provides measurements really equivalent to HVPG in terms of gradient accuracy.

Participants undergoing HVPG will first undergo the procedure while conscious, performed by the first operator. Immediately thereafter, HVPG will be repeated following the induction of anesthesia by a second operator blinded to the initial readings. Subsequently, EUS-PPG will be performed by an endoscopist, who will also be blinded to all previous pressure measurements.

Conditions

• Cirrhosis
• Portal Hypertension
• EUS
• Non-Cirrhotic Portal Hypertension
• HVPG
• Hepatic Venous Pressure Gradient

Interventions

PROCEDURE

Hepatic venous pressure gradient measurement

HVPG measurement is minimally invasive procedure that involves cannulation of the right internal jugular vein, followed by the insertion of a balloon-occlusion catheter into the right or middle hepatic vein to measure both free hepatic vein pressure and wedged hepatic vein pressure, enabling the calculation of HVPG. Additionally, this method allows for liver biopsy during the same session. HVPG is widely regarded as the gold standard for PPG measurement.

PROCEDURE

Endoscopic ultrasound-guided portal pressure gradient measurement

Recent advancements in the field of digestive endoscopy have introduced an innovative alternative: endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) measurement. This emerging technique shows promise for further improving the accessibility of portal hypertension assessment and also offers the possibility of liver biopsy in one session. EUS-PPG may have several advantages, including its minimally invasive nature, safety profile, high technical success rate, the possibility of a "one-stopshop" approach (combining EUS-PPG, liver biopsy, and endoscopic treatment of esophageal varices), absence of radiation exposure.

Sponsors & Collaborators

• University Hospital Prague (IKEM), Prague, Czech Republic

  collaborator UNKNOWN

• Military University Hospital, Prague

  lead OTHER

Principal Investigators

• Petr Hříbek, MD, PhD · Military University Hospital, Prague

Study Design

Allocation

NA

Purpose

DIAGNOSTIC

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-05-30

Primary Completion

2027-12-31

Completion

2028-12-31

Countries

• Czechia

Study Locations